Substrate and method for production thereof

Abstract

The present invention relates to a substrate including a compound having blood anticoagulation activity and a hydrophilic polymer compound, wherein the amount of elution of the compound having blood anticoagulation activity is less than 0.6 μg/ml, and a manufacturing method of a substrate, wherein after a compound having blood anticoagulation activity and a hydrophilic compound brought in contact with a substrate are irradiated with radiation, unreacted components are washed out.

1 . A substrate, comprising a compound having blood anticoagulation activity and a hydrophilic polymer compound,
 wherein the amount of elution of the compound having blood anticoagulation activity is less than 0.6 μg/ml.   
     
     
         2 . The substrate according to  claim 1 , wherein 1 ng/cm 2  or more of the compound having blood anticoagulation activity is contained on the substrate surface. 
     
     
         3 . The substrate according to  claim 1 , wherein the compound having blood anticoagulation activity has antithrombin activity and the amount of thrombin adsorption is 1.0 ng/cm 2  or more. 
     
     
         4 . The substrate according to  claim 2 , wherein the compound having blood anticoagulation activity has antithrombin activity and the amount of thrombin adsorption is 1.0 ng/cm 2  or more. 
     
     
         5 . The substrate according to  claim 1 , wherein surface hydrophilic high molecular weight of the hydrophilic polymer compound is 20% by weight or more. 
     
     
         6 . The substrate according to  claim 1 , wherein the compound having blood anticoagulation activity contains a blood anticoagulation activity portion and a polymer chain portion. 
     
     
         7 . The substrate according to  claim 6 , wherein the polymer chain portion has hydrophilicity. 
     
     
         8 . The substrate according to  claim 7 , wherein the polymer chain portion contains at least one selected from a propylene glycol residue, a polyvinyl pyrolidone residue, a polypropylene glycol residue, a polyvinyl alcohol residue, and a residue of a copolymer of one residue thereof. 
     
     
         9 . The substrate according to  claim 8 , comprising a polyvinyl alcohol residue whose saponification degree is 50 mol % or more and 99.9 mol % or less. 
     
     
         10 . The substrate according to  claim 7 , wherein the compound having the blood anticoagulation activity is 4-methoxy-benzenesulfonyl-Asn(PEG2000-Ome)-Pro-4-amidinoben zylamido. 
     
     
         11 . The substrate according to  claim 8 , wherein the compound having the blood anticoagulation activity is 4-methoxy-benzenesulfonyl-Asn(PEG2000-Ome)-Pro-4-amidinoben zylamido. 
     
     
         12 . The substrate according to  claim 9 , wherein the compound having the blood anticoagulation activity is 4-methoxy-benzenesulfonyl-Asn(PEG2000-Ome)-Pro-4-amidinoben zylamido. 
     
     
         13 . The substrate according to  claim 1 , wherein the hydrophilic polymer compound contains at least one selected from a group consisting of polyvinyl alcohol, polyether, polyvinyl pyrolidone, and a material composed of polyether and polysiloxane. 
     
     
         14 . The substrate according to  claim 13 , wherein the material composed of polyether and polysiloxane is a polyether/polysiloxane copolymer. 
     
     
         15 . The substrate according to  claim 13 , wherein the polyether of the material composed of polyether and polysiloxane includes polyethylene glycol and polypropylene glycol. 
     
     
         16 . The substrate according to  claim 14 , wherein the polyether of the polyether/polysiloxane copolymer includes polyethylene glycol and polypropylene glycol. 
     
     
         17 . The substrate according to  claim 14 , wherein the polyether of the polyether/polysiloxane copolymer includes polypropylene glycol and the content of the polypropylene glycol in the polyether/polysiloxane copolymer is 5 mol % or more and 90 mol % or less. 
     
     
         18 . The substrate according to  claim 15 , wherein content of polypropylene glycol in the polyether/polysiloxane copolymer is 5 mol % or more and 90 mol % or less.